JP4193218B2 - Biotin dissolution method and biotin-containing internal solution - Google Patents
Biotin dissolution method and biotin-containing internal solution Download PDFInfo
- Publication number
- JP4193218B2 JP4193218B2 JP22804797A JP22804797A JP4193218B2 JP 4193218 B2 JP4193218 B2 JP 4193218B2 JP 22804797 A JP22804797 A JP 22804797A JP 22804797 A JP22804797 A JP 22804797A JP 4193218 B2 JP4193218 B2 JP 4193218B2
- Authority
- JP
- Japan
- Prior art keywords
- biotin
- aspartate
- dissolving
- magnesium
- dissolution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、ビオチンの溶解方法及びビオチンを含有する内服液剤に関する。
【0002】
【従来の技術】
ビオチンは、ビタミンHとも称され皮膚、毛髪を正常に維持するために必要なビタミンである。一般的なドリンク剤のpH域である酸性域(2〜5)ではビオチンは水に難溶性であり、その溶解には工夫が必要であった。
ビオチンを溶解する手法としては、従来、ポリビニルピロリドンを使用する方法(特開平7−76520号)や水酸化アルカリなどを使用して中性〜アルカリ性に調整した後にビオチンを溶解する方法などが知られている。
しかし、ポリビニルピロリドンは共存成分と反応して沈殿を生成する場合や、他のビタミンやアミノ酸などの配合成分と反応して成分を低下させる場合がある。また、水酸化アルカリなどを使用する方法は、中性〜アルカリ性でビオチンを溶解しても、内服液剤のpHである酸性域に戻した場合、ビオチンが経時的に析出してしまうことがある(特開平7−76520号)。析出しないまでも、薬効上不必要な成分を添加しなければならないことや調製が煩雑になることなど、必ずしも好ましい方法であるとは言えない。
【0003】
【発明が解決しようとする課題】
本発明の目的は、製剤上不必要な成分を追加することなく迅速かつ容易に水へビオチンを溶解させる方法及びビオチンを含有する内服液剤を提供することにある。
【0004】
【課題を解決するための手段】
本発明者らは上記目的について鋭意研究した結果、ビオチンを緩衝能を有するアミノ酸塩の水溶液に別途溶解した場合、所期の目的を達成することを見いだし、本発明を完成した。
すなわち、本発明は、緩衝能を有するアミノ酸塩の水溶液にビオチンを溶解することを特徴とするビオチンの溶解方法である。他の本発明は、ビオチンと緩衝能を有するアミノ酸塩を含有し、pHが2〜5の範囲であることを特徴とする内服液剤である。他の本発明は、ビオチン及びビオチンを溶解するための緩衝能を有するアミノ酸塩を含有する内服液剤である。
【0005】
【発明の実施の形態】
本発明における緩衝能を有するアミノ酸塩とは、例えばアスパラギン酸塩を挙げることができる。アスパラギン酸塩としては、アスパラギン酸マグネシウム・カリウム、アスパラギン酸マグネシウム、アスパラギン酸カリウムの1種又はこれらを組み合わせであり、就中アスパラギン酸マグネシウム・カリウムが好ましい。
【0006】
本発明のビオチンの溶解方法は、緩衝能を有するアミノ酸類を水に溶解し、次いでビオチンを溶解することにより達成される。また、本発明のビオチン含有内服液剤は、まず前記の如く緩衝能を有するアミノ酸類の水溶液にビオチンを溶解し、別途各種配合成分を溶解した液を調製して、両液を混合後、必要に応じてpHを調整することによって製造される。
【0007】
ビオチンを溶解するための緩衝能を有するアミノ酸塩の濃度はpHなどにより異なるが、例えばビオチン0.2mgを溶解するためには通常は50〜500mg、好ましくは100〜300mgを水100mlに溶解した水溶液50〜100mlが用いられる。以下、溶解するビオチン量によって緩衝能を有するアミノ酸塩の水溶液の量が決定される。
【0008】
さらに、本発明の内服液剤には、上記成分の他、通常内服液剤に用いることの可能な配合成分、例えば各種ビタミン(例えばビタミンA、ビタミンC、ビタミンD、ビタミンE、ビタミンP又はそれらの塩、エステルもしくは誘導体など)、アミノ酸(例えばタウリン、L−アスパラギン酸、L−アルギニン、トリプトファン、リジンなど)、生薬(例えばムイラプアマ、ニンジン、ジオウなど)、カフェイン、ローヤルゼリー、多価アルコール(例えばプロピレングリコールなど)、有機酸(例えばクエン酸、リンゴ酸、乳酸、コハク酸など)、ミネラル成分(例えばグルコン酸カルシウム、乳酸カルシウム、クエン酸鉄アンモニウムなど)、香料、保存剤などを本発明の効果を損なわない範囲で配合することができる。
【0009】
【発明の効果】
本発明により、ビオチンの溶解のために薬効上不要な成分を追加することなく迅速かつ容易な溶解方法が提供されるとともに、酸性域でも経時的に安定でかつ各種配合成分も補給できるビオチン含有内服液剤が提供された。
【0010】
【実施例】
以下、実施例及び試験例を挙げて本発明を更に詳細に説明する。
実施例1
タウリン 2000mg
ビオチン 200μg
アスパラギン酸マグネシウム・カリウム 200mg
マルチトール 1500mg
ビタミンB6 5mg
クエン酸(pH調整剤) 適量
クエン酸ナトリクム 10mg
安息香酸ナトリウム 70mg
ステビア抽出物 30mg
香料 微量
精製水 全量100ml(pH3.5)
精製水80mlにアスパラギン酸マグネシウム・カリウムを溶解後、撹拌しながらビオチンを添加し溶解した。その後、タウリン、マルチトール、ビタミンB6、クエン酸ナトリウム、安息香酸ナトリウム、ステビア抽出物、香料の順に添加して溶解したことを確認後、精製水を加え全量を100mlに調整し、クエン酸を添加してpHを3.5に調整することにより、内服液剤を得た。
【0011】
実施例2
タウリン 1000mg
ビオチン 200μg
アスパラギン酸マグネシウム 200mg
ビタミンB2 5mg
ソルビトール 2000mg
マルチトール 9000mg
リンゴ酸 100mg
クエン酸(pH調整剤) 適量
安息香酸ナトリウム 60mg
ステビア抽出物 25mg
香料 微量
精製水 全量100ml(pH2.8)
上記各成分について、実施例1と同様な方法により、滋養強壮用内服液剤を得た。
【0012】
実施例3
タウリン 1000mg
ビオチン 200μg
アスパラギン酸マグネシウム・カリウム 200mg
ビタミンB1硝酸塩 2mg
エリスリトール 5000mg
リンゴ酸 100mg
クエン酸(pH調整剤) 適量
ニパブチ 4mg
ステビア抽出物 15mg
精製水 全量100ml(pH4.0)
上記各成分について、実施例1と同様な方法により、滋養強壮用内服液剤を得た。
【0013】
試験例[溶解性試験]
▲1▼実施例1について、精製水80mlにアスパラギン酸マグネシウム・カリウム200mgを溶解後、室温下撹拌しながらビオチンを200μg添加したところ、10分後にビオチンの溶解を確認した。これに処方中の他の成分を溶解後精製水で全量を100mlに調整し、次いでクエン酸を添加してpHを3.5に調整した。これを5℃で1週間保存した結果、ビオチンの析出は見られなかった。
【0014】
▲2▼実施例2について、精製水80mlにアスパラギン酸マグネシウム200mgを溶解後、室温下撹拌しながらビオチン200μgを添加したところ、10分後にビオチンの溶解を確認した。これを▲1▼と同様に調整後5℃で1週間保存した結果、ビオチンの析出は見られなかった。
【0015】
▲3▼室温において精製水80mlにビオチン200μgを添加して撹拌しながら溶解を試みたところ、60分後に溶解していなかった。
【0016】
▲4▼80〜90℃に維持した精製水80mlに撹拌しながらビオチン200μgを添加し、溶解を試みたところ、60分後に溶解していなかった。
【0017】
▲5▼精製水80mlにクエン酸ナトリウム10mgを溶解後、撹拌しながらビオチン200μgを添加し溶解を試みたところ、60分後には溶解していなかった。
【0018】
▲6▼80〜90℃に維持した精製水80mlにクエン酸ナトリウム10mgを溶解後、撹拌しながらビオチン200μgを添加し溶解を試みたところ、60分後には溶解していなかった。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a method for dissolving biotin and an internal solution containing biotin.
[0002]
[Prior art]
Biotin is also called vitamin H and is a vitamin necessary for maintaining normal skin and hair. In the acidic range (2 to 5), which is the pH range of general drinks, biotin is hardly soluble in water, and some contrivance is required for its dissolution.
Conventional methods for dissolving biotin include a method using polyvinyl pyrrolidone (Japanese Patent Laid-Open No. 7-76520) and a method of dissolving biotin after adjusting to neutral to alkaline using alkali hydroxide or the like. ing.
However, polyvinyl pyrrolidone may react with a coexisting component to produce a precipitate, or may react with other ingredients such as vitamins and amino acids to lower the component. In addition, the method using alkali hydroxide or the like is neutral to alkaline, and even if biotin is dissolved, if it is returned to the acidic range that is the pH of the internal solution, biotin may precipitate over time ( JP-A-7-76520). Even if it does not precipitate, it is not necessarily a preferable method, for example, it is necessary to add a component that is not necessary for medicinal effects, and the preparation becomes complicated.
[0003]
[Problems to be solved by the invention]
An object of the present invention is to provide a method for rapidly and easily dissolving biotin in water without adding unnecessary components in the preparation and an internal solution containing biotin.
[0004]
[Means for Solving the Problems]
As a result of diligent research on the above object, the present inventors have found that when biotin is separately dissolved in an aqueous solution of an amino acid salt having a buffering capacity, the intended object is achieved, and the present invention has been completed.
That is, the present invention is a biotin dissolution method characterized by dissolving biotin in an aqueous solution of an amino acid salt having a buffering capacity. Another aspect of the present invention is an internal solution containing biotin and an amino acid salt having a buffering capacity and having a pH in the range of 2 to 5. Another aspect of the present invention is an internal liquid solution containing biotin and an amino acid salt having a buffering capacity for dissolving biotin.
[0005]
DETAILED DESCRIPTION OF THE INVENTION
Examples of the amino acid salt having a buffering capacity in the present invention include aspartate. Aspartate is one or a combination of magnesium and potassium aspartate, magnesium aspartate, and potassium aspartate, with magnesium and potassium aspartate being particularly preferred.
[0006]
The method for dissolving biotin of the present invention is achieved by dissolving amino acids having a buffer capacity in water and then dissolving biotin. In addition, the biotin-containing oral solution of the present invention is prepared by first dissolving biotin in an aqueous solution of amino acids having a buffering capacity as described above, separately preparing a solution in which various compounding components are dissolved, mixing both solutions, and then necessary. It is manufactured by adjusting the pH accordingly.
[0007]
The concentration of the amino acid salt having a buffering capacity for dissolving biotin varies depending on pH and the like. For example, in order to dissolve 0.2 mg of biotin, the aqueous solution is usually 50 to 500 mg, preferably 100 to 300 mg dissolved in 100 ml of water. 50-100 ml is used. Hereinafter, the amount of an aqueous solution of an amino acid salt having a buffer capacity is determined by the amount of biotin dissolved.
[0008]
Furthermore, the internal liquid preparation of the present invention includes, in addition to the above components, compounding ingredients that can be used in normal internal liquid preparations, such as various vitamins (for example, vitamin A, vitamin C, vitamin D, vitamin E, vitamin P, or salts thereof). , Esters or derivatives), amino acids (eg, taurine, L-aspartic acid, L-arginine, tryptophan, lysine, etc.), herbal medicines (eg, muirapuama, carrot, diau, etc.), caffeine, royal jelly, polyhydric alcohols (eg, propylene glycol) Etc.), organic acids (eg, citric acid, malic acid, lactic acid, succinic acid, etc.), mineral components (eg, calcium gluconate, calcium lactate, ammonium iron citrate, etc.), perfumes, preservatives, etc. It can mix | blend in the range which is not.
[0009]
【The invention's effect】
According to the present invention, a biotin-containing internal medicine that provides a quick and easy dissolution method without adding unnecessary components for the dissolution of biotin, is stable over time in the acidic region, and can be replenished with various components. A solution was provided.
[0010]
【Example】
Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples.
Example 1
Taurine 2000mg
Biotin 200μg
Magnesium and potassium aspartate 200mg
Maltitol 1500mg
Vitamin B6 5mg
Citric acid (pH adjuster) appropriate amount sodium citrate 10mg
Sodium benzoate 70mg
Stevia extract 30mg
Fragrance Trace purified water 100ml (pH3.5)
After dissolving magnesium potassium aspartate in 80 ml of purified water, biotin was added and dissolved while stirring. After confirming that taurine, maltitol, vitamin B6, sodium citrate, sodium benzoate, stevia extract, and fragrance were added and dissolved in that order, purified water was added to adjust the total volume to 100 ml, and citric acid was added. By adjusting the pH to 3.5, an internal solution was obtained.
[0011]
Example 2
Taurine 1000mg
Biotin 200μg
Magnesium aspartate 200mg
Vitamin B2 5mg
Sorbitol 2000mg
Maltitol 9000mg
Malic acid 100mg
Citric acid (pH adjuster) appropriate amount Sodium benzoate 60mg
Stevia extract 25mg
Fragrance Micropurified water 100ml (pH 2.8)
About each said component, the internal liquid preparation for nourishing tonic was obtained by the same method as Example 1.
[0012]
Example 3
Taurine 1000mg
Biotin 200μg
Magnesium and potassium aspartate 200mg
Vitamin B1 nitrate 2mg
Erythritol 5000mg
Malic acid 100mg
Citric acid (pH adjuster) appropriate amount nipabuchi 4mg
Stevia extract 15mg
Purified water 100ml (pH 4.0)
About each said component, the internal liquid preparation for nourishing tonic was obtained by the same method as Example 1.
[0013]
Test example [Solubility test]
{Circle around (1)} In Example 1, 200 mg of biotin was added after dissolving 200 mg of magnesium / potassium aspartate in 80 ml of purified water and stirred at room temperature, and dissolution of biotin was confirmed after 10 minutes. To this, other components in the formulation were dissolved and the total amount was adjusted to 100 ml with purified water, and then citric acid was added to adjust the pH to 3.5. As a result of storage at 5 ° C. for 1 week, biotin precipitation was not observed.
[0014]
{Circle around (2)} In Example 2, 200 mg of biotin was added with stirring at room temperature after dissolving 200 mg of magnesium aspartate in 80 ml of purified water, and dissolution of biotin was confirmed after 10 minutes. This was adjusted in the same manner as in (1) and stored at 5 ° C. for 1 week. As a result, no biotin precipitation was observed.
[0015]
(3) When 200 μg of biotin was added to 80 ml of purified water at room temperature and dissolution was attempted with stirring, it was not dissolved after 60 minutes.
[0016]
(4) 200 μg of biotin was added to 80 ml of purified water maintained at 80 to 90 ° C. with stirring, and dissolution was attempted. However, dissolution was not observed after 60 minutes.
[0017]
(5) After dissolving 10 mg of sodium citrate in 80 ml of purified water and adding 200 μg of biotin with stirring, dissolution was attempted, but after 60 minutes, it was not dissolved.
[0018]
(6) After dissolving 10 mg of sodium citrate in 80 ml of purified water maintained at 80 to 90 ° C., 200 μg of biotin was added with stirring, and dissolution was attempted.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22804797A JP4193218B2 (en) | 1996-09-05 | 1997-08-25 | Biotin dissolution method and biotin-containing internal solution |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8-234795 | 1996-09-05 | ||
| JP23479596 | 1996-09-05 | ||
| JP22804797A JP4193218B2 (en) | 1996-09-05 | 1997-08-25 | Biotin dissolution method and biotin-containing internal solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10130146A JPH10130146A (en) | 1998-05-19 |
| JP4193218B2 true JP4193218B2 (en) | 2008-12-10 |
Family
ID=26528018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP22804797A Expired - Fee Related JP4193218B2 (en) | 1996-09-05 | 1997-08-25 | Biotin dissolution method and biotin-containing internal solution |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4193218B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7036504B2 (en) * | 2017-12-25 | 2022-03-15 | ハウスウェルネスフーズ株式会社 | Biotin-containing acidic composition with excellent biotin stability |
| JP7678403B2 (en) * | 2020-04-02 | 2025-05-16 | 大正製薬株式会社 | drinking composition |
| JP7678402B2 (en) * | 2020-04-02 | 2025-05-16 | 大正製薬株式会社 | drinking composition |
-
1997
- 1997-08-25 JP JP22804797A patent/JP4193218B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10130146A (en) | 1998-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4051717B2 (en) | Biotin-containing oral solution | |
| ES2236300T3 (en) | IRON COMPOSITIONS. | |
| FI120080B (en) | Pharmaceutical compositions with antibiotic activity | |
| JP4193218B2 (en) | Biotin dissolution method and biotin-containing internal solution | |
| JPH1192402A (en) | Formulation composition and its production | |
| JPH09502709A (en) | Oral, water-soluble pharmaceutical composition containing estrone derivative and calcium salt | |
| JP2006052169A (en) | Sol-like or gel-like administration assistant food | |
| JP4134358B2 (en) | Biotin dissolution method and oral solution | |
| JP4029431B2 (en) | Iron compound combination oral solution | |
| JP2000239173A (en) | Oral liquid composition containing iron compound | |
| JP4206506B2 (en) | Solution containing vitamin B1 | |
| JP4216916B2 (en) | Drinking liquid composition | |
| JP2001010955A (en) | Oral solution composition | |
| JP4678079B2 (en) | Riboflavin formulation solution composition | |
| JPH11171793A (en) | Vitamin B1 compound liquid | |
| JP2002531392A (en) | Preparation and use of dry compositions that are soluble in the presence of water and prevent the Meyer reaction in the dry state | |
| JPH09286724A (en) | Liquid stablizer for oral administration | |
| JP4228403B2 (en) | Solution containing vitamin B1 | |
| JP2006045215A (en) | Zinc-containing oral solution | |
| JP2000044469A (en) | Oral solution | |
| JP3122921B2 (en) | Biotin-containing solution for internal use | |
| JP2000239153A (en) | Oral liquid composition containing iron compound | |
| US20050008699A1 (en) | Effervescent glucosamine composition | |
| JP2665764B2 (en) | Calcium aqueous solution | |
| JP2003515553A (en) | Effervescent histamine H2 antagonist composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040722 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080617 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080812 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080812 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080902 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080915 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121003 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121003 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131003 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131003 Year of fee payment: 5 |
|
| LAPS | Cancellation because of no payment of annual fees |